Personalis gains on agreement with Moderna
- Personalis Inc and Moderna Inc have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies of mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co Inc .
- The platform, also utilized in the vaccine candidate's Phase 2b study, will be used to sequence genomic information from a patient's tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
- In January, Personalis approved a reduction in its workforce by up to approximately 30% to reduce operating costs and improve operating efficiency.
- The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.